Axabin®

Features:

• Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation (NVAF)
• Treatment of deep vein thrombosis (DVT)
• Treatment of pulmonary embolism (PE)
• Reduction in the risk of recurrence of DVT or PE
• Prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery

• Prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients
• Axabin® is the first generic form of rivaroxaban in Iran which is produced at a GMP approved manufacturing site